RESUMO
OBJECTIVES: An increasing prevalence since 2010 of Serratia marcescens harbouring the Ambler class A carbapenemase SME prompted us to further characterize these isolates. METHODS: Isolates harbouring bla(SME) were identified by PCR and sequencing. Phenotypic analysis for carbapenemase activity was carried out by a modified Hodge test and a modified Carba NP test. Antimicrobial susceptibilities were determined by Etest and Vitek 2. Typing was by PFGE of macrorestriction digests. Whole-genome sequencing of three isolates was carried out to characterize the genomic region harbouring the bla(SME)-type genes. RESULTS: All S. marcescens harbouring SME-type enzymes could be detected using a modified Carba NP test. Isolates harbouring bla(SME) were resistant to penicillins and carbapenems, but remained susceptible to third-generation cephalosporins, as well as fluoroquinolones and trimethoprim/sulfamethoxazole. Isolates exhibited diverse genetic backgrounds, though 57% of isolates were found in three clusters. Analysis of whole-genome sequence data from three isolates revealed that the bla(SME) gene occurred in a novel cryptic prophage genomic island, SmarGI1-1. CONCLUSIONS: There has been an increasing occurrence of S. marcescens harbouring bla(SME) in Canada since 2010. The bla(SME) gene was found on a genomic island, SmarGI1-1, that can be excised and circularized, which probably contributes to its dissemination amongst S. marcescens.
Assuntos
Proteínas de Bactérias/análise , Proteínas de Bactérias/genética , Ilhas Genômicas , Infecções por Serratia/microbiologia , Serratia marcescens/enzimologia , Serratia marcescens/genética , beta-Lactamases/análise , beta-Lactamases/genética , Adulto , Idoso , Idoso de 80 Anos ou mais , Canadá , DNA Bacteriano/genética , Eletroforese em Gel de Campo Pulsado , Feminino , Transferência Genética Horizontal , Variação Genética , Humanos , Sequências Repetitivas Dispersas , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Dados de Sequência Molecular , Tipagem Molecular , Reação em Cadeia da Polimerase , Análise de Sequência de DNA , Serratia marcescens/isolamento & purificaçãoRESUMO
OBJECTIVES: This study examined Klebsiella pneumoniae clinical isolates and their bla(KPC) plasmids to determine potential relatedness of the isolates and their plasmids harbouring carbapenem resistance mechanisms. METHODS: K. pneumoniae carbapenemase (KPC)-producing K. pneumoniae from New York City (NYC) (nâ=â19) and Toronto (nâ=â2) were typed by PFGE and multilocus sequence typing (MLST). bla(KPC)-harbouring plasmids were transformed into Escherichia coli DH10B(TM), restricted using EcoRI and analysed for bla content and replicon (rep) type. Susceptibility profiles for clinical and transformed strains were determined by automated microbroth dilution using CLSI breakpoints. Outer membrane protein (OMP) genes were analysed by sequencing of ompk35 and ompk36. RESULTS: PFGE analysis identified 17 related strains (≥ 80% similarity; 11 KPC-2, 6 KPC-3) where ST258 was the dominant clonal type. All clinical isolates contained both bla(SHV) and bla(TEM-1) and, with the exception of one isolate, were multidrug resistant (MDR). Transformed KPC plasmids (nâ=â21) carried TEM-1 (nâ=â18) and were MDR (nâ=â5). Three plasmid clusters, repFIIA (nâ=â10), repR (nâ=â3) and an unknown type (nâ=â3), were observed. repFllA plasmids were observed from both NYC and Toronto strains. OMP gene analysis revealed premature stop codons in ompk35 and numerous deletions and insertions in ompk36. CONCLUSIONS: The dissemination of bla(KPC) is due both to carriage of similar KPC-harbouring plasmids within genetically distinct K. pneumoniae and to clonal spread of K. pneumoniae with unrelated KPC plasmids.
Assuntos
Infecções por Klebsiella/microbiologia , Klebsiella pneumoniae/enzimologia , Klebsiella pneumoniae/genética , Plasmídeos , Resistência beta-Lactâmica , beta-Lactamases/genética , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/farmacologia , Proteínas da Membrana Bacteriana Externa/genética , Técnicas de Tipagem Bacteriana , Canadá , Carbapenêmicos/farmacologia , Eletroforese em Gel de Campo Pulsado , Feminino , Transferência Genética Horizontal , Humanos , Klebsiella pneumoniae/classificação , Klebsiella pneumoniae/isolamento & purificação , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Epidemiologia Molecular , Tipagem Molecular , Tipagem de Sequências Multilocus , Cidade de Nova Iorque , Transformação BacterianaRESUMO
OBJECTIVE: To describe MRSA infection and colonization in household pets, and transmission of MRSA between animals and humans. METHODS: MRSA infection and colonization in household pets and human contacts were evaluated during investigations initiated after identification of MRSA infection or colonization of a household pet in order to determine if there had been transmission between animals and humans. All MRSA isolates were screened for Panton-Valentine leukocidin (PVL) genes by use of polymerase chain reaction, and isolate relatedness was determined by use of pulsed-field gel electrophoresis (PFGE). RESULTS: Investigations of six situations where MRSA was identified in one or more animals in a household or veterinary facility were performed. MRSA was isolated from 8 animals (5 dogs and 3 cats) with clinical infections, 1 cat that was in contact with 2 infected cats and 14/88 (16%) of household contacts or veterinary personnel. Both animal-to-human and human-to-animal transmission were suspected. An indistinguishable MRSA isolate was recovered from at least one human that was in contact with each animal case. All isolates were classified as Canadian epidemic MRSA-2, the predominant community-associated MRSA clone in humans in Canada. No isolates possessed genes encoding for the PVL. CONCLUSIONS: Transmission of MRSA between humans and animals, in both directions, was suspected. MRSA appears to be an emerging veterinary and zoonotic pathogen.
Assuntos
Doenças do Gato/transmissão , Doenças do Cão/transmissão , Resistência a Meticilina , Infecções Estafilocócicas/transmissão , Staphylococcus aureus/efeitos dos fármacos , Zoonoses , Animais , Doenças do Gato/microbiologia , Gatos , Infecção Hospitalar , Doenças do Cão/microbiologia , Cães , Eletroforese em Gel de Campo Pulsado , Hospitais Veterinários , Humanos , Testes de Sensibilidade Microbiana , Doenças Profissionais/microbiologia , Exposição Ocupacional , Reação em Cadeia da Polimerase , Staphylococcus aureus/isolamento & purificaçãoRESUMO
There are increasing reports of methicillin-resistant Staphylococcus aureus (MRSA) infection and colonization in horses and evidence that MRSA can be transmitted between horses and humans. The objective of this study was to investigate reports of skin infection in personnel working with a foal with community-associated MRSA colonization and subsequent infection. Clinical diagnostic specimens were collected from individuals reporting skin lesions following contact with the affected foal. Nasal and groin screening swabs were collected from other veterinary personnel that attended a voluntary screening clinic. MRSA skin infections were identified in three neonatal intensive care unit personnel. Nasal colonization was subsequently identified in 10/103 (9.7%) other veterinary hospital personnel. Isolates were indistinguishable by pulsed field gel electrophoresis, classified as Canadian epidemic MRSA-5, possessed SCCmecIV, were negative for the Panton-Valentine leukocidin and were multidrug resistant. Transmission to veterinary personnel despite short-term contact with standard protective barriers highlights the potential importance of MRSA as an emerging zoonotic pathogen, and indicates that further evaluation of interspecies transmission of MRSA and means to prevent zoonotic infection are required.
Assuntos
Doenças dos Cavalos/transmissão , Infecções Cutâneas Estafilocócicas/microbiologia , Infecções Cutâneas Estafilocócicas/transmissão , Staphylococcus aureus/isolamento & purificação , Zoonoses/microbiologia , Zoonoses/transmissão , Adulto , Animais , Animais Recém-Nascidos , Infecções Comunitárias Adquiridas , Surtos de Doenças , Eletroforese em Gel de Campo Pulsado/métodos , Feminino , Ácido Fusídico/administração & dosagem , Doenças dos Cavalos/microbiologia , Cavalos , Hospitais Veterinários , Humanos , Resistência a Meticilina , Mupirocina/administração & dosagem , Rifampina/administração & dosagem , Infecções Cutâneas Estafilocócicas/tratamento farmacológico , Infecções Cutâneas Estafilocócicas/epidemiologia , Staphylococcus aureus/classificação , Staphylococcus aureus/efeitos dos fármacos , Resultado do TratamentoRESUMO
Methicillin-resistant Staphylococcus aureus (MRSA) is an emerging equine pathogen. To attempt to control nosocomial and zoonotic transmission, an MRSA screening program was established for all horses admitted to the Ontario Veterinary College Veterinary Teaching Hospital, whereby nasal screening swabs were collected at admission, weekly during hospitalization, and at discharge. MRSA was isolated from 120 (5.3%) of 2,283 horses: 61 (50.8%) at the time of admission, 53 (44.2%) during hospitalization, and 6 from which the origin was unclear because an admission swab had not been collected. Clinical infections attributable to MRSA were present or developed in 14 (11.7%) of 120 horses. The overall rate of community-associated colonization was 27 per 1,000 admissions. Horses colonized at admission were more likely to develop clinical MRSA infection than those not colonized at admission (OR 38.9, 95% CI 9.49 160, P < 0.0001). The overall nosocomial MRSA colonization incidence rate was 23 per 1,000 admissions. The incidence rate of nosocomial MRSA infection was at the rate of 1.8 per 1,000 admissions, with an incidence density of 0.88 per 1,000 patient days. Administration of ceftiofur or aminoglycosides during hospitalization was the only risk factor associated with nosocomial MRSA colonization. MRSA screening of horses admitted to a veterinary hospital was useful for identification of community-associated and nosocomial colonization and infection, and for monitoring of infection control practices.
Assuntos
Doenças dos Cavalos/microbiologia , Cavalos/microbiologia , Hospitais Veterinários , Resistência a Meticilina , Infecções Estafilocócicas/veterinária , Staphylococcus aureus/isolamento & purificação , Staphylococcus aureus/fisiologia , Animais , Portador Sadio , Estudos de Casos e Controles , Infecções Comunitárias Adquiridas/microbiologia , Infecções Comunitárias Adquiridas/veterinária , Infecção Hospitalar/microbiologia , Infecção Hospitalar/veterinária , Doenças dos Cavalos/epidemiologia , Ontário/epidemiologia , Fatores de Risco , Infecções Estafilocócicas/epidemiologia , Infecções Estafilocócicas/microbiologia , Staphylococcus aureus/efeitos dos fármacosRESUMO
BACKGROUND: Vancomycin-resistant enterococci (VRE) were first detected in our institution in 1991. An outbreak was recognized in late 1992 when there was a sudden rise in the number of patients per month with VRE. Little information exists concerning the natural history of infection with these pathogens, and the effect of antimicrobial therapy is unclear. Recent guidelines emphasize prudent use of vancomycin and prompt institution of barrier precautions to limit the spread of vancomycin resistance. METHODS: Data were obtained by review of microbiologic and clinical records. Patients were categorized according to site of infection, and outcome of therapy was assessed. Hospital antibiotic usage was analyzed to determine any correlation with the outbreak. Infection control measures instituted in 1993 included patient isolation, environmental cleaning, and a reemphasis of barrier precautions. Surveillance cultures were performed to assess the extent of the outbreak in January 1995. RESULTS: VRE were detected in clinical cultures from 159 patients from 1991 through 1994. Mortality rate was 48%, but in most cases death could not be attributed to enterococcal infection. Patients with wound infections healed without specific therapy. Many patients with bacteremia had resolution with ampicillin or without specific therapy. Patients were widely scattered throughout the hospital from the beginning of the outbreak. Hospital usage of cefotaxime correlated with the number of cases. Infection control measures were not successful. Surveillance culture results in January 1995 revealed that 53% of all medical and surgical inpatients had fecal colonization with VRE. Genetic analysis of selected isolates revealed that one strain predominated, but at least seven distinct strains were identified. CONCLUSIONS: Our data suggest that many infections with VRE resolve without specific therapy. The infection control measures we used were ineffective, possibly because of the multiple strains present in our hospital. Isolation of all patients with VRE is impractical when there is widespread fecal carriage.
Assuntos
Antibacterianos/uso terapêutico , Infecção Hospitalar/epidemiologia , Surtos de Doenças , Enterococcus/efeitos dos fármacos , Controle de Infecções/métodos , Vancomicina/farmacologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Infecção Hospitalar/tratamento farmacológico , Infecção Hospitalar/mortalidade , Resistência Microbiana a Medicamentos , Enterococcus/isolamento & purificação , Métodos Epidemiológicos , Hospitais de Veteranos , Humanos , Pessoa de Meia-Idade , Cidade de Nova Iorque/epidemiologia , Estudos RetrospectivosRESUMO
Escherichia coli may become resistant to cephamycines and oxyimino cephalosporins by virtue of promotor and attenuator mutations or because they have acquired mobilized beta-lactamases from other gram-negative bacilli. This study examined Canadian strains to determine how often promotor and/or attenuator mutations account for this mechanism of resistance and the extent to which clonal spread of these organisms has occurred. We sequenced the promotor and attenuator region of 30 strains resistant to cefoxitin. Twenty-two strains had promotor mutations, 26 had attenuator mutations. Most promotor mutations resulted either in a change in the -35 promotor region towards the E. coli sigma 70 consensus sequence or in the creation of a new consensus hexamer upstream. Eight strains had mutations that increased the typical ampC 16-nucleotide spacer region to the consensus 17- or an 18-nucleotide sequence. Of the attenuator mutations, most did not substantially affect the attenuator loop. Several of the mutations have previously been described in South Africa, Scandinavia, and France. There was evidence that strains bearing certain mutations were clonally disseminated; however, the 11 strains bearing a complex set of attenuator mutations were not. The majority of cephamycin resistant E. coli strains in Toronto have attenuator and/or promotor mutations upstream of the chromosomal ampC gene.
Assuntos
Cefoxitina/farmacologia , Cefamicinas/farmacologia , Escherichia coli/efeitos dos fármacos , Escherichia coli/genética , Resistência beta-Lactâmica/genética , Impressões Digitais de DNA , DNA Bacteriano/análise , Eletroforese em Gel de Campo Pulsado , Infecções por Escherichia coli/epidemiologia , Infecções por Escherichia coli/microbiologia , Genes Bacterianos , Humanos , Mutação , Ontário/epidemiologia , Reação em Cadeia da Polimerase , Análise de Sequência de DNARESUMO
Enterococci have become important nosocomial pathogens, with Enterococcus faecalis and then Enterococcus faecium predominating. Because of the emergence of glycopeptide (vancomycin and teicoplanin) resistance in enterococci, laboratories have been required to screen for resistant strains and to identify them to the species level. This has resulted in the need for accurate identification of species less commonly associated with clinical infections, such as Enterococcus casseliflavus and Enterococcus gallinarum, which are inherently resistant to the glycopeptides. Studies evaluating commonly used commercial identification systems, have found error rates for enterococcal species identification of 2-21% for E. faecalis, 5-9% for E. faecium, and 14-79% for other species. Reporting errors may have adverse effects on the management of clinical infections, as well as in the control of multidrug-resistant strain outbreaks. The purpose of this document is to present a simplified approach to the identification of Enterococcus species that uses a combination of rapid, readily available, and inexpensive tests.
Assuntos
Técnicas de Tipagem Bacteriana , Técnicas Bacteriológicas , Enterococcus/classificação , Infecções por Bactérias Gram-Positivas/microbiologia , Antibacterianos/farmacologia , Técnicas de Tipagem Bacteriana/economia , Técnicas Bacteriológicas/economia , Análise Custo-Benefício , Resistência Microbiana a Medicamentos , Enterococcus/efeitos dos fármacos , Enterococcus/isolamento & purificação , Humanos , Testes de Sensibilidade Microbiana , Especificidade da Espécie , Vancomicina/farmacologiaRESUMO
The enterococcus has become an important nosocomial pathogen, reported by the National Nosocomial Infections Surveillance System as the third most common pathogen associated with blood-stream infections and the second most commonly isolated pathogen overall. It is now more frequently recognized as a cause of superinfection in the surgical patient, as the possible result of the frequent use of ineffective antimicrobials for prophylaxis and treatment. Both of these findings are due, in part, to the intrinsic antimicrobial resistance of the enterococci. Of greater concern is the ready ability of this organism to acquire resistance traits. During the past 5 years, the appearance and rapid dissemination of strains with high-level resistance to vancomycin, ampicillin, gentamicin, and streptomycin have been reported; in some cases, no effective antimicrobial therapy was available to patients infected with these strains. Enterococci, in addition to their intrinsic and acquired tolerance to beta-lactams, have acquired the ability to inactivate penicillin and ampicillin via beta-lactamase production. Prompt recognition of such multiresistant enterococci, the implementation of effective infection control precautions, and rational use of antimicrobials may limit or even prevent the spread of such strains in the hospital setting.
Assuntos
Antibacterianos/farmacologia , Enterococcus/efeitos dos fármacos , Enterococcus/patogenicidade , Infecções por Bactérias Gram-Positivas/tratamento farmacológico , Complicações Pós-Operatórias , Antibacterianos/uso terapêutico , Resistência Microbiana a Medicamentos , Humanos , LactamasAssuntos
Técnicas de Tipagem Bacteriana , Enterococcus/classificação , Infecção Hospitalar/microbiologia , DNA Bacteriano/genética , Surtos de Doenças , Resistência Microbiana a Medicamentos , Enterococcus/efeitos dos fármacos , Enterococcus/genética , Técnicas Genéticas , Infecções por Bactérias Gram-Positivas/microbiologia , Humanos , Controle de Infecções , Testes de Sensibilidade MicrobianaRESUMO
Three commercially available real-time reverse transcriptase PCR assays (the Artus RealArt HPA coronavirus LightCycler, the Artus RealArt HPA coronavirus Rotor-Gene, and the EraGen severe acute respiratory syndrome coronavirus POL assay) and three RNA extraction methodologies were evaluated for the detection of severe acute respiratory syndrome coronavirus RNA from 91 stool specimens. The assays' sensitivities were highest (58% to 75%) for specimens obtained 8 to 21 days after symptom onset. The assays were less sensitive when specimens were obtained less than 8 days or more than 21 days after the onset of symptoms. All assays were 100% specific.
Assuntos
Fezes/virologia , Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos , Coronavírus Relacionado à Síndrome Respiratória Aguda Grave/isolamento & purificação , Humanos , RNA Viral/isolamento & purificação , Coronavírus Relacionado à Síndrome Respiratória Aguda Grave/genética , Sensibilidade e EspecificidadeRESUMO
Methicillin-resistant Staphylococcus aureus (MRSA) infection was identified in 2 horses treated at a veterinary hospital in 2000, prompting a study of colonization rates of horses and associated persons. Seventy-nine horses and 27 persons colonized or infected with MRSA were identified from October 2000 to November 2002; most isolations occurred in a 3-month period in 2002. Twenty-seven (34%) of the equine isolates were from the veterinary hospital, while 41 (51%) were from 1 thoroughbred farm in Ontario. Seventeen (63%) of 27 human isolates were from the veterinary hospital, and 8 (30%) were from the thoroughbred farm. Thirteen (16%) horses and 1 (4%) person were clinically infected. Ninety-six percent of equine and 93% of human isolates were subtypes of Canadian epidemic MRSA-5, spa type 7 and possessed SCCmecIV. All tested isolates from clinical infections were negative for the Panton-Valentine leukocidin genes. Equine MRSA infection may be an important emerging zoonotic and veterinary disease.
Assuntos
Cavalos/microbiologia , Staphylococcus aureus/isolamento & purificação , Criação de Animais Domésticos , Técnicos em Manejo de Animais , Animais , Portador Sadio , Reservatórios de Doenças , Doenças dos Cavalos/epidemiologia , Doenças dos Cavalos/microbiologia , Humanos , Resistência a Meticilina , Ontário/epidemiologia , Infecções Estafilocócicas/epidemiologia , Infecções Estafilocócicas/veterinária , Staphylococcus aureus/classificação , Staphylococcus aureus/efeitos dos fármacos , Estudantes de Ciências da Saúde , Fatores de Tempo , Médicos VeterináriosRESUMO
A total of 154 Enterococcus faecium and 48 Enterococcus faecalis isolates, 55% of which were ampicillin-resistant, were used to evaluate two commonly used automated systems, Vitek's GPS-TA card (bioMérieux, USA) and MicroScan's POS MIC Type 6 panel (Baxter Health-care, USA), and the NCCLS disk diffusion method for the detection of ampicillin resistance. MicroScan panels were read by the Walk/Away system and by visual inspection. The results were as follows: disk diffusion, 100% sensitive and specific; Vitek, 100% sensitive and 95% specific; and MicroScan, when read by the Walk/Away, 85% sensitive and 98% specific. When MicroScan was interpreted by visual inspection, however, sensitivity increased to 96%.
Assuntos
Resistência a Ampicilina , Enterococcus faecalis/efeitos dos fármacos , Enterococcus faecium/efeitos dos fármacos , Testes de Sensibilidade Microbiana/métodos , HumanosRESUMO
The genus Enterococcus consists of at least 12 species, two of which account for over 95% of the clinically important strains, E faecalis (85%-90%) and E faecium (5%-10%). Despite their ubiquity and frequent isolation, they have not been thought to cause serious disease because they lack common virulence factors. Now, however, enterococci are regarded as true pathogens and are the second leading cause of nosocomial infections. This change results from their increasing antimicrobial resistance and the extensive use of antimicrobial drugs (for example-cephalosporins) that are not active against them. Serious infections should usually be treated with a beta-lactam and an aminoglycoside, but glycopeptides have been increasingly used during the last decade. Two novel resistance patterns of particular concern recently are high level aminoglycoside resistance (HLAR) and vancomycin resistance. The prevalence of HLAR is between 15% and 55%, and glycopeptide resistance has become widespread in various geographical areas. This poses a serious problem, as such resistance may spread to other Gram-positive organisms and is often associated with resistance to other antimicrobial drugs. This may theoretically result in groups of organisms for which there will be no effective antimicrobial treatment.
Assuntos
Enterococcus , Abscesso Abdominal/microbiologia , Aminoglicosídeos , Antibacterianos/farmacologia , Infecção Hospitalar/microbiologia , Resistência Microbiana a Medicamentos , Quimioterapia Combinada/farmacologia , Enterococcus/efeitos dos fármacos , Enterococcus/enzimologia , Infecções por Bactérias Gram-Positivas/microbiologia , Humanos , Ácido Penicilânico/análogos & derivados , Ácido Penicilânico/farmacologia , Piperacilina/farmacologia , Tazobactam , Vancomicina/farmacologia , Inibidores de beta-Lactamases , beta-Lactamases/biossínteseRESUMO
Cross-contamination with laboratory control strains of vancomycin-resistant Enterococcus faecalis was documented in 15 clinical specimens from nine clinical microbiology laboratories in Ontario, Canada. Laboratories should be alert to the possibility of contamination of specimens with vancomycin-resistant enterococci from the laboratory environment. Molecular typing of strains may assist in elucidating the source of such contamination.
Assuntos
Enterococcus faecalis/efeitos dos fármacos , Enterococcus faecalis/isolamento & purificação , Contaminação de Equipamentos , Laboratórios/normas , DNA Bacteriano/genética , DNA Bacteriano/isolamento & purificação , Eletroforese em Gel de Campo Pulsado , Enterococcus faecalis/classificação , Enterococcus faecalis/genética , Enterococcus faecium/classificação , Enterococcus faecium/efeitos dos fármacos , Enterococcus faecium/genética , Enterococcus faecium/isolamento & purificação , Microbiologia Ambiental , Genótipo , Humanos , Ontário , Controle de Qualidade , Resistência a Vancomicina/genéticaRESUMO
To determine the validity of the rapid xylose and methyl-alpha-D-glucopyranoside (MDG) fermentation tests in distinguishing Enterococcus gallinarum from Enterococcus faecium, 156 well-characterized clinical isolates of enterococci (55 E. gallinarum, 91 E. faecium, and 10 Enterococcus faecalis isolates) known to be of different clones were examined in a blinded fashion. Species identification was confirmed by PCR of the ddl ligase genes of E. faecium and E. faecalis and the vanC1 gene of E. gallinarum. Xylose tests were performed with D-xylose tablets by using a heavy bacterial suspension and were interpreted after 2 h of incubation. Standard MDG fermentation tests were read after 24 h of incubation. The xylose fermentation test had a sensitivity of 98% (54 of 55) and a specificity of 99% (100 of 101) in distinguishing E. gallinarum from E. faecium and E. faecalis. The standard MDG test had a sensitivity of 100% (55 of 55) and a specificity of 95% (96 of 101) after 24 h. The xylose fermentation test is a simple method, easily incorporated into laboratory protocols, that distinguishes E. gallinarum from E. faecium with high sensitivity and specificity in 2 h. The standard MDG test has high sensitivity and can be useful in ruling out the presence of E. gallinarum but requires overnight incubation.
Assuntos
Enterococcus faecium/classificação , Enterococcus/classificação , Metilglucosídeos/metabolismo , Xilose/metabolismo , Proteínas de Bactérias/genética , Técnicas de Tipagem Bacteriana , Eletroforese em Gel de Campo Pulsado , Enterococcus/genética , Enterococcus/isolamento & purificação , Enterococcus faecium/genética , Enterococcus faecium/isolamento & purificação , Reações Falso-Positivas , Fermentação , Humanos , Testes de Sensibilidade Microbiana , Peptídeo Sintases/genética , Sensibilidade e Especificidade , Teicoplanina/farmacologia , Vancomicina/farmacologia , Resistência a VancomicinaRESUMO
We report a case of group C streptococcal meningitis in a woman with a history of close animal contact as well as head trauma as a result of a kick by a horse. Blood and cerebrospinal fluid cultures grew Streptococcus equi subsp. zooepidemicus, as did a throat culture taken from the colt that had kicked her 2 weeks prior to admission.
Assuntos
Doenças dos Cavalos/microbiologia , Meningites Bacterianas/transmissão , Infecções Estreptocócicas/transmissão , Streptococcus equi/isolamento & purificação , Zoonoses , Animais , Feminino , Doenças dos Cavalos/transmissão , Cavalos , Humanos , Meningites Bacterianas/microbiologia , Pessoa de Meia-Idade , Infecções Estreptocócicas/microbiologia , Infecções Estreptocócicas/veterináriaRESUMO
Antibiotic resistant strains of enterococci are being isolated with increasing frequency. Effective treatment of infections caused by Enterococcus faecium resistant to ampicillin, vancomycin and aminoglycosides has not been established. We studied the activity of ramoplanin, a new lipoglycopeptide antibiotic, against two strains of multidrug resistant E. faecium. In time kill studies, ramoplanin was bactericidal against both strains, but not in the presence of 50% serum. The combination of ramoplanin and penicillin was bactericidal even in the presence of serum. In rabbits with experimental endocarditis neither penicillin nor ramoplanin significantly reduced vegetation colony counts when given alone, although ramoplanin significantly reduced spleen and kidney bacterial counts of both strains. The combination of ramoplanin plus penicillin resulted in a significant reduction of vegetation bacterial counts (-3.2 and -3.7 log10 cfu/g for strains VA3 and MMC3, respectively, P < 0.01). All spleen cultures and 9 out of 10 kidney cultures from each strain were sterile following combination therapy. While ramoplanin will not be available for parenteral therapy, further research into the development of other lipoglycopeptide antibiotics is warranted.
Assuntos
Antibacterianos/uso terapêutico , Depsipeptídeos , Endocardite Bacteriana/tratamento farmacológico , Enterococcus faecium/efeitos dos fármacos , Penicilinas/uso terapêutico , Peptídeos Cíclicos , Animais , Resistência Microbiana a Medicamentos , Resistência a Múltiplos Medicamentos , Endocardite Bacteriana/etiologia , Enterococcus faecium/isolamento & purificação , Rim/microbiologia , Testes de Sensibilidade Microbiana , Plantas/microbiologia , Coelhos , Baço/microbiologiaRESUMO
The in vitro activity of cefdinir (CI-983; FK-482), a new oral cephalosporin, was compared with that of other antimicrobial agents against clinical isolates of staphylococci, gram-negative bacilli and common respiratory tract pathogens. Cefdinir (MIC90 less than or equal to 2.0 micrograms/ml) was more active than cefixime (MIC90 greater than 64 micrograms/ml) and equally as active as cefuroxime (MIC90 2.0 micrograms/ml) against oxacillin-susceptible staphylococci. Cefdinir was active against Haemophilus influenzae, including beta-lactamase producers (MIC90 0.5 microgram/ml), Moraxella catarrhalis (MIC90 less than or equal to 0.12 microgram/ml), Streptococcus pneumoniae (MIC90 less than or equal to 0.06 microgram/ml) and Streptococcus pyogenes (MIC90 less than or equal to 0.06 microgram/ml). The activity of cefdinir against gram-negative bacilli was variable; organisms with chromosomal cephalosporinases were often resistant.
Assuntos
Bactérias/efeitos dos fármacos , Cefalosporinas/farmacologia , Bactérias Gram-Negativas/efeitos dos fármacos , Sistema Respiratório/microbiologia , Staphylococcus/efeitos dos fármacos , Cefdinir , Testes de Sensibilidade MicrobianaRESUMO
Stenotrophomonas (Xanthomonas) maltophilia is inherently resistant to multiple antimicrobial agents. In order to investigate the in vitro potential of combinations of antimicrobial agents, we obtained 230 epidemiologically unrelated clinical isolates from seven hospitals across Canada and from Northwestern Memorial Hospital in Chicago. Ticarcillin-clavulanate combined with ciprofloxacin or trimethoprim-sulfamethoxazole were assayed for synergy against 31 ticarcillin-resistant strains of S. maltophilia by using microtiter checkerboard panels and against 20 strains by using time-kill methodology. The combination of ciprofloxacin with ceftazidime was also evaluated by time-kill studies. Ticarcillin-clavulanate plus trimethoprim-sulfamethoxazole demonstrated synergy by checkerboard panels, with fractional inhibitory concentration indices ranging from 0.033 to 0.49, and by time-kill studies for all 20 strains tested. Synergy between ticarcillin-clavulanate plus ciprofloxacin was found by the checkerboard method for 24 of 31 strains (77%), with fractional inhibitory concentration indices ranging from 0.188 to 0.75. A correlation between synergy by the checkerboard method and the reference time-kill study method was not observed for ticarcillin-clavulanate plus ciprofloxacin, with results for 3 of 10 strains being nonconcordant. Synergy with both ticarcillin-clavulanate plus ciprofloxacin and ceftazidime plus ciprofloxacin by the time-kill method was found to correlate with ciprofloxacin MICs of <32 micrograms/ml and zone diameters of >15 mm on Mueller-Hinton agar. Evaluation of these combinations in vivo may be warranted.